Paul Mampilly is an investment expert and financial manager. His primary investment client, the Banyan Hill released a report in Profits Unlimited indicating the 47 % increase Mampilly had made in one year. The unique ideas, proprietary method and hands-on trading experiences he gained in over 25 years have seen him make superior returns in his investments.
The big winners
In January 2016, Paul Mampilly opened a demonstration account for a client with $5,000 real cash. They generated gains of more than 180 % from this investment. The greatest beneficiary was the Coeur Mining Company who made 700+%. Nvidia and ETF made 100% profits under the Capuchin Consulting.
In October 2011 and December 2012, Paul Mampilly recommended 29 stocks for the Palm Beach Letter. By the year 2013, the recommendations were up by 53 %, with an addition of 28 stocks. Yahoo made +157 % profit, Boston Scientific made +126 %, and Interparfums made +117 % profits.
Paul Mampilly managed a private account between 2008 and 2009, which won the prestigious Templeton Foundation Investment Award. The account had made 76 % investment returns. In 2009, Mampilly was the manager of Kinetic International Fund, a firm that made 67 % profits.
Follow Paul Mampilly on LinkedIn
Mr. Paul Mampilly founded the Capuchin Consulting in 2013. The company was dedicated to providing unique money-making investment ideas and professional investment assistance. Through the Capuchinomics publications, he focused exclusively on behavioral finance and was read by influential hedge fund managers and investment firms. It offered a unique system where human emotion was the factor number one in decision making preceding an investment.
Financial analyst of the FDA trader and author
Mampilly was the author, editor and the analyst for the Agora Financials, a Life Science and Bio Technology firm for the FDA Trader. FDA generated over $6 million in profit sales under the tenure of Paul Mampilly and was also listed as the number one source of biotech investment research. As an investment Director, the ideas, commentaries, and research he provided for the Agora Financials generated a 62 % profit for the FDA Trader portfolio. Paul Mampilly managed a team of two analysts covering healthcare stocks. In this capacity, he was able to recommend stocks to three portfolio managers and was wholly responsible for the additional shares purchased by the three new directors.